MIM
KRTX

Monashee Investment Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Monashee Investment Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-28,500
Closed -$5.18M – 90
2023
Q1 		$5.18M Buy
+28,500
New +$5.45M 1.43% 13
2019
Q3 		– Sell
-110,000
Closed -$2.2M – 186
2019
Q2 		$2.2M Buy
+110,000
New +$2.2M 0.57% 49

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Monashee Investment Management's KRTX Position: Q2 2023 in Review

Monashee Investment Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 28,500 shares — an estimated $5.18M sold.

Monashee Investment Management first reported a position in KRTX in Q2 2019 and held it in 2 quarters. The position peaked at $5.18M in Q1 2023. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Monashee Investment Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Monashee Investment Management sold 28,500 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.18M.
  • Monashee Investment Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Monashee Investment Management's Karuna Therapeutics, Inc. Common Stock position peaked at $5.18M in Q1 2023.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Monashee Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.